Payment overview · 2025
General Payments
$710.04
22 reported records · 9 companies
Healthcare provider profile · identity verified
Willie A Pennick, MD
Allopathic & Osteopathic Physicians|Family Medicine · JACKSONVILLE, FL · NPI 1568426302
Verified facts
What the public records show
CMS Open Payments records show Willie A Pennick, MD received $710.04 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $213.15 | 30.0% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.00 | 17.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $98.02 | 13.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $72.36 | 10.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.66 | 9.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.11 | 7.3% | 3 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $39.02 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.73 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.99 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $710.04 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $122.40 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $90.75 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $72.36 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.11 | 3 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $39.02 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 436 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 217 | 71 |
| Furosemide | Furosemide | 183 | 60 |
| Losartan Potassium | Losartan Potassium | 174 | 53 |
| Carvedilol | Carvedilol | 164 | 48 |
| Omeprazole | Omeprazole | 131 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 35 |
| Gabapentin | Gabapentin | 123 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 36 |
| Alprazolam | Alprazolam | 103 | 22 |
| Metformin Hcl | Metformin Hcl | 96 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 31 |
| Lisinopril | Lisinopril | 89 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 32 |
| Potassium Chloride | Potassium Chloride | 85 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 83 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 26 |
| Ozempic | Semaglutide | 79 | 20 |
| Eliquis | Apixaban | 78 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 18 |
| Trazodone Hcl | Trazodone Hcl | 70 | 15 |
| Montelukast Sodium | Montelukast Sodium | 68 | 21 |
| Donepezil Hcl | Donepezil Hcl | 64 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 14 |
| Meloxicam | Meloxicam | 63 | 23 |
| Jardiance | Empagliflozin | 62 | 12 |
| Alendronate Sodium | Alendronate Sodium | 57 | 16 |
| Allopurinol | Allopurinol | 57 | 16 |
| Tramadol Hcl | Tramadol Hcl | 57 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 16 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 54 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 21 |
| Amoxicillin | Amoxicillin | 49 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 17 |
| Januvia | Sitagliptin Phosphate | 48 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 11 |
| Spironolactone | Spironolactone | 45 | 15 |
| Simvastatin | Simvastatin | 43 | 12 |
| Azithromycin | Azithromycin | 42 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 36 |
| Ezetimibe | Ezetimibe | 40 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 12 |
| Celecoxib | Celecoxib | 37 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 23 |
| Prednisone | Prednisone | 36 | 28 |
| Nifedipine Er | Nifedipine | 35 | 13 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 11 |
| Meclizine Hcl | Meclizine Hcl | 34 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 34 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 25 |
| Telmisartan | Telmisartan | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | 11 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 13 |
| Metformin Hcl Er | Metformin Hcl | 28 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | 12 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 15 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 13 |
| Lorazepam | Lorazepam | 23 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 23 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Glyxambi | Empagliflozin/Linagliptin | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | 13 |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 11 |
| Estradiol | Estradiol | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $710.04 · 22 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, CeQur Simplicity, Cologuard Collection Kit, FARXIGA, Kerendia, MOUNJARO, PREVNAR 20, SHINGRIX, Veozah, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error